Crestline Management LP Invests $1.25 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Crestline Management LP bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 23,414 shares of the company's stock, valued at approximately $1,254,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. RA Capital Management L.P. increased its stake in shares of Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company's stock worth $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Janux Therapeutics by 47.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock worth $163,926,000 after buying an additional 986,750 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Janux Therapeutics by 596.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock valued at $59,429,000 after acquiring an additional 950,557 shares in the last quarter. FMR LLC lifted its stake in shares of Janux Therapeutics by 10.8% during the 4th quarter. FMR LLC now owns 8,669,941 shares of the company's stock worth $464,189,000 after acquiring an additional 845,266 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Janux Therapeutics by 1,165.6% during the fourth quarter. Bank of America Corp DE now owns 794,761 shares of the company's stock valued at $42,552,000 after purchasing an additional 731,962 shares during the period. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

JANX traded down $2.11 on Wednesday, hitting $23.22. The company had a trading volume of 713,350 shares, compared to its average volume of 859,859. Janux Therapeutics, Inc. has a 52-week low of $22.52 and a 52-week high of $71.71. The firm has a market capitalization of $1.37 billion, a P/E ratio of -19.85 and a beta of 3.24. The stock has a fifty day simple moving average of $29.06 and a 200-day simple moving average of $41.29.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $30.00, for a total transaction of $100,020.00. Following the completion of the transaction, the insider now owns 82,139 shares in the company, valued at approximately $2,464,170. This represents a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. The trade was a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 10,001 shares of company stock worth $313,964 over the last three months. 8.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Scotiabank cut their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush restated an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of "Buy" and an average target price of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.